Apple said it is restoring blood-oxygen monitoring to Apple Watch models sold in the United States, 18 months after the feature was stripped to comply with an International Trade Commission order tied to patent claims from medical-device maker Masimo. A software update rolling out today—iOS 18.6.1 for iPhone and watchOS 11.6.1 for the Watch—enables a redesigned version of the tool for Series 9, Series 10 and Ultra 2 devices that had shipped without it. Under the redesign, sensor data are collected on the watch but processed on the paired iPhone, with results displayed in the Health app. Apple said the workaround was cleared in a recent U.S. Customs ruling, allowing the company to resume importing the affected watches while it pursues an appeal of the ITC decision. Units sold before January 2024 or outside the United States keep the original on-watch blood-oxygen feature. Separately, Boston-based Whoop told the U.S. Food and Drug Administration it will continue offering a blood-pressure tracking function on its screen-less Whoop MG band, despite a July FDA warning that the capability may qualify as an unapproved medical device. The company maintains the feature is intended for general wellness and has asked to meet with regulators, underscoring heightened scrutiny of health sensors in consumer wearables.